Dropped head syndrome: a rare adverse drug reaction identified in the FDA adverse event reporting system and review of case reports in the literature

References

• Drain JP, Virk SS, Jain N, et al. Dropped head syndrome: a systematic review. Clin Spine Surg. 32(10): 423–429. 2019.
   PubMed Web of Science ®Google Scholar
• Brodell JD Jr., Sulovari A, Bernstein DN, et al. Dropped head syndrome: an update on etiology and surgical management. JBJS Rev. 8(1): e0068. 2020.
   PubMed Web of Science ®Google Scholar
• Quinn N. Disproportionate antecollis in multiple system atrophy. Lancet. 1989;1(8642):844.
   PubMed Web of Science ®Google Scholar
• Suarez GA, Kelly JJ Jr. The dropped head syndrome. Neurology. 1992;42(8):1625–1627.
   PubMed Web of Science ®Google Scholar
• Katz JS, Wolfe GI, Burns DK, et al. Isolated neck extensor myopathy: a common cause of dropped head syndrome. Neurology. 1996;46(4):917–921.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Mukohara S, Hatachi S, et al. A case of myositis with dropped head syndrome and anti-titin antibody positivity induced by pembrolizumab. Scand J Rheumatol. 2020;49(6):509–511.
   PubMed Web of Science ®Google Scholar
• Akaishi T, Kikuchi A, Hasegawa T, et al. Case report: suspected DPP-4 inhibitor-induced dropped head syndrome. Nihon Naika Gakkai Zasshi. 2013;102(6):1464–1466.
   PubMedGoogle Scholar
• Taguchi Y, Takashima S, Tanaka K. Pramipexole-induced dropped head syndrome in Parkinson’s disease. Intern Med. 2008;47(22):2011–2012.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Takayama Y. Licorice-induced hypokalemia as a treatable cause of dropped head syndrome. Clin Neurol Neurosurg. 2003;105(4):286–287.
   PubMed Web of Science ®Google Scholar
• Kleemann J, Hrgovic I, Hempel K, et al. Dropped-head syndrome in a patient under treatment with the MEK inhibitor trametinib for NRAS-mutated metastatic melanoma. Clin Exp Dermatol. 2018;43(2):195–196.
   PubMed Web of Science ®Google Scholar
• Chen X, Schwartz GK, DeAngelis LM, et al. Dropped head syndrome: report of three cases during treatment with a MEK inhibitor. Neurology. 79(18): 1929–1931. 2012.
   PubMed Web of Science ®Google Scholar
• King A, Diamond E, Orozco J, et al. Cobimetinib-induced “dropped head syndrome” and subsequent disease management in an Erdheim-Chester patient. Clin Case Rep. 2019;7(10):1989–1993.
   PubMed Web of Science ®Google Scholar
• Longvert C, Maisonobe T, Saiag P, et al. On/off dropped head syndrome: a severe adverse event after prolonged treatment with MEK inhibitor. Eur J Cancer. 2018;91:174–176.
   PubMed Web of Science ®Google Scholar
• Weaver J, Willy M, Avigan M. Informatic tools and approaches in postmarketing pharmacovigilance used by FDA. AAPS J. 2008;10(1):35–41.
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Sommet A, Bagheri H, et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905–908.
   PubMed Web of Science ®Google Scholar
• Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf. 2003;26(3):159–186.
   PubMed Web of Science ®Google Scholar
• Szarfman A, Machado S, O’Neill R. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database. Drug Saf. 2002;25(6):381–392.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Yanagihashi M, Sawada M, et al. Donepezil-induced cervical dystonia in Alzheimer’s disease: a case report and literature review of dystonia due to cholinesterase inhibitors. Intern Med. 2014;53(9):1007–1010.
   PubMed Web of Science ®Google Scholar
• Savica R, Kumar N, Ahlskog J, et al. Parkinsonism and dropped head: dystonia, myopathy or both? Parkinsonism Relat Disord. 2012;18(1):30–34.
   PubMed Web of Science ®Google Scholar
• Burakgazi A, Richardson P, Abu-Rub M. Dropped head syndrome due to neuromuscular disorders: clinical manifestation and evaluation. Neurol Int. 2019;11(3):8198.
   PubMed Web of Science ®Google Scholar
• Mano T. Reversal of dropped head syndrome after the cessation of dopaminergic agonist treatment in parkinson disease. Clin Neuropharmacol. 2017;40(5):219–220.
   PubMed Web of Science ®Google Scholar
• Oyama G, Hayashi A, Mizuno Y, et al. Mechanism and treatment of dropped head syndrome associated with parkinsonism. Parkinsonism Relat Disord. 2009;15(3):181–186.
   PubMed Web of Science ®Google Scholar
• Kataoka H, Ueno S. Dropped head associated with amantadine in Parkinson disease. Clin Neuropharmacol. 2011;34(1):48–49.
   PubMed Web of Science ®Google Scholar
• Ameghino L, Rossi M, Cammarota A, et al. Ropinirole-induced anterocollis in Parkinson’s disease. Mov Disord Clin Pract. 2016;3(1):91–92.
   PubMedGoogle Scholar
• Hussaini S, Chehade R, Boldt R, et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis. Cancer Treat Rev. 2021;92:102134.
   PubMed Web of Science ®Google Scholar
• Greco A, Safi D, Swami U, et al. Efficacy and adverse events in metastatic melanoma patients treated with combination BRAF Plus MEK inhibitors versus BRAF inhibitors: a systematic review. Cancers (Basel). 2019;11(12):1950.
   PubMed Web of Science ®Google Scholar
• Boasberg PD, Redfern CH, Daniels GA, et al. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother Pharmacol. 2011;68(2):547–552.
   PubMed Web of Science ®Google Scholar
• Prado C, Bekaii-Saab T, Doyle L, et al. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer. 2012;106(10):1583–1586.
   PubMed Web of Science ®Google Scholar
• Szuch E, Caress JB, Paudyal B, et al. Head drop after botox: electrodiagnostic evaluation of iatrogenic botulinum toxicity. Clin Neurol Neurosurg. 2017;156:1–3.
   PubMed Web of Science ®Google Scholar
• Antonucci F, Rossi C, Gianfranceschi L, et al. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci. 2008;28(14):3689–3696.
   PubMed Web of Science ®Google Scholar
• Umapathi T, Chaudhry V, Cornblath D, et al. Head drop and camptocormia. J Neurol Neurosurg Psychiatry. 2002;73(1):1–7.
   PubMed Web of Science ®Google Scholar